Compare Stocks: PEPG, AURA, CLYM, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$3.75 -2.1%	$5.11	$2.10 ▼ $6.60	$524.34M	0.87	3.91 million shs	2.29 million shs
AURA Aura Biosciences	$6.30 -2.5%	$6.83	$4.73 ▼ $9.53	$653.34M	0.41	940,909 shs	721,844 shs
CLYM Climb Bio	$10.19 -3.3%	$13.31	$1.63 ▼ $18.33	$585.27M	-0.04	1.03 million shs	495,679 shs
PEPG PepGen	$2.52 -6.7%	$2.81	$1.31 ▼ $7.80	$174.54M	2.01	1.05 million shs	1.16 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+14.33%	-30.30%	-28.30%	+65.93%
AURA Aura Biosciences	0.00%	+3.28%	+2.44%	-10.64%	+9.38%
CLYM Climb Bio	0.00%	+3.77%	-14.30%	-20.64%	+394.66%
PEPG PepGen	0.00%	-3.08%	-5.97%	+30.57%	-44.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$3.75 -2.1%	$5.11	$2.10 ▼ $6.60	$524.34M	0.87	3.91 million shs	2.29 million shs
AURA Aura Biosciences	$6.30 -2.5%	$6.83	$4.73 ▼ $9.53	$653.34M	0.41	940,909 shs	721,844 shs
CLYM Climb Bio	$10.19 -3.3%	$13.31	$1.63 ▼ $18.33	$585.27M	-0.04	1.03 million shs	495,679 shs
PEPG PepGen	$2.52 -6.7%	$2.81	$1.31 ▼ $7.80	$174.54M	2.01	1.05 million shs	1.16 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+14.33%	-30.30%	-28.30%	+65.93%
AURA Aura Biosciences	0.00%	+3.28%	+2.44%	-10.64%	+9.38%
CLYM Climb Bio	0.00%	+3.77%	-14.30%	-20.64%	+394.66%
PEPG PepGen	0.00%	-3.08%	-5.97%	+30.57%	-44.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	202.22% Upside
AURA Aura Biosciences	2.33	Hold	$17.50	177.78% Upside
CLYM Climb Bio	3.00	Buy	$27.64	171.27% Upside
PEPG PepGen	2.67	Moderate Buy	$11.40	352.38% Upside

Current Analyst Ratings Breakdown

Latest PEPG, AURA, CLYM, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	CLYM Climb Bio	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$28.00
10/15/2026	CLYM Climb Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/12/2026	AURA Aura Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/12/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	CLYM Climb Bio	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy	$34.00
9/22/2026	PEPG PepGen	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	ACRS Aclaris Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/16/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/9/2026	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$24.00 ➝ $30.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	66.96	N/A	N/A	$0.85 per share	4.41
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.16 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$2.14 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
AURA Aura Biosciences	-$106.19M	-$1.75	N/A	N/A	N/A	N/A	-73.18%	-62.00%	11/5/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
PEPG PepGen	-$89.65M	-$1.31	N/A	N/A	N/A	N/A	-51.01%	-43.49%	11/11/2026 (Estimated)

Latest PEPG, AURA, CLYM, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	CLYM Climb Bio	-$0.20	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	PEPG PepGen	-$0.27	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	ACRS Aclaris Therapeutics	-$0.16	N/A	N/A	N/A	$1.23 million	N/A
11/5/2026	Q3 2026	AURA Aura Biosciences	-$0.3681	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	-$0.48	-$0.1050	-$0.48	N/A	N/A
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/6/2026	Q2 2026	PEPG PepGen	-$0.2845	-$0.26	+$0.0245	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
AURA Aura Biosciences	N/A	16.82	16.82
CLYM Climb Bio	N/A	31.45	31.45
PEPG PepGen	N/A	13.36	13.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
AURA Aura Biosciences	96.75%
CLYM Climb Bio	69.76%
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
AURA Aura Biosciences	1.90%
CLYM Climb Bio	2.60%
PEPG PepGen	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	73	139.82 million	133.11 million	Optionable
AURA Aura Biosciences	113	103.71 million	101.74 million	Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	Optionable
PEPG PepGen	57	69.26 million	68.36 million	Optionable

PEPG, AURA, CLYM, and ACRS Headlines

Recent News About These Companies

PepGen (NASDAQ:PEPG) Stock Moved Down to Sell by Wall Street Zen

October 10, 2026 | marketbeat.com

PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated “Moderate Buy” by Wall Street Analysts

October 5, 2026 | defenseworld.netD

PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated "Moderate Buy" by Wall Street Analysts

October 5, 2026 | marketbeat.com

PepGen Inc. (PEPG) Interactive Stock Chart - Yahoo Finance

September 16, 2026 | finance.yahoo.com

DSMB approves dose escalation in PepGen’s FREEDOM2-DM1 study

August 7, 2026 | msn.com

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

August 6, 2026 | businesswire.com

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 6, 2026 | businesswire.com

PepGen Inc. (PEPG) Stock Price, News, Quote & History - Yahoo Finance

July 14, 2026 | finance.yahoo.com

PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

July 8, 2026 | stockhouse.com

PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

May 20, 2026 | zacks.com

10 Best NASDAQ Stocks Under $5 to Buy Right Now

May 18, 2026 | insidermonkey.com

Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?

May 18, 2026 | finance.yahoo.com

PepGen (PEPG) Upgraded to Buy: Here's What You Should Know

May 13, 2026 | zacks.com

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 12, 2026 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

May 7, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 30, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 28, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)

April 26, 2026 | theglobeandmail.com

Stifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)

April 26, 2026 | theglobeandmail.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

April 16, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PEPG, AURA, CLYM, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$3.75 -0.08 (-2.09%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$3.76 +0.00 (+0.13%)

As of 10/23/2026 07:30 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aura Biosciences NASDAQ:AURA

$6.30 -0.16 (-2.48%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$6.28 -0.02 (-0.38%)

As of 10/23/2026 07:30 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Climb Bio NASDAQ:CLYM

$10.19 -0.35 (-3.32%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$10.18 -0.01 (-0.10%)

As of 10/23/2026 07:30 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

PepGen NASDAQ:PEPG

$2.52 -0.18 (-6.67%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$2.52 0.00 (-0.20%)

As of 10/23/2026 07:59 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, AURA, CLYM, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, AURA, CLYM, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, AURA, CLYM, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEPG, AURA, CLYM, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Aura Biosciences NASDAQ:AURA

Climb Bio NASDAQ:CLYM

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PEPG, AURA, CLYM, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PEPG, AURA, CLYM, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PEPG, AURA, CLYM, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PEPG, AURA, CLYM, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Aura Biosciences NASDAQ:AURA

Climb Bio NASDAQ:CLYM

PepGen NASDAQ:PEPG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools